1,00,000 per cent multibagger returns; Board announced bonus shares in ratio 3:1; don’t miss!

The stock gave multibagger returns of 500 per cent in just 1 year, 5,670 per cent in 5 years and a whopping 1,00,000 per cent in a decade.

Shukra Pharmaceuticals Ltd inform you that the meeting of the Board of Directors of the company approved the issue of bonus shares in the proportion of 3: 1 i.e., 3 fully paid-up bonus equity share of Rs 10 each for every 1 fully paid-up equity shares of Rs 10 each held by the members of the company as on the record date, subject to the approval of members of the company rough postal ballot.

Pre-bonus paid-up share capital: 1,09,46,986 shares having paid-up of Rs 10 each per share and post-bonus paid-up share capital: 4,37,87,944 shares having paid-up value of Rs 10 each per share.

Today, shares of Shukra Pharmaceuticals Ltd were locked in a 5 per cent upper circuit to Rs 319.45 per share from its previous closing of Rs 304.25. The stock also traded at a new 52-week high of Rs 319.45 while its 52-week low is Rs 41.76.

Established in 1993, Shukra Pharmaceuticals Ltd. operates in both manufacturing and trading pharmaceuticals, alongside offering laboratory testing services. The company has a market cap of over Rs 349.70 crore with a 3-year stock price CAGR of 200 per cent.

The company reported positive results in both quarterly and annual financial statements. In Q3FY24, net sales rose by 721 per cent to Rs 18.89 crore and net profit skyrocketed 314 times to Rs 9.42 per cent compared to Q3FY23. In FY22, the company did net sales of Rs 20.48 crore and net profit skyrocketed 295 per cent.

According to the shareholding, the promoters own a 50.95 per cent stake in the company while DIIs own 0.11 per cent and the public owns 48.94 per cent as of December 2023. The stock gave multibagger returns of 500 per cent in just 1 year, 5,670 per cent in 5 years and a whopping 1,00,000 per cent in a decade. Investors should keep an eye on this micro-cap stock.

Disclaimer: The article is for informational purposes only and not investment advice.